Fig. 2: Baseline HER2 expression in primary and exploratory cohorts. | Nature Medicine

Fig. 2: Baseline HER2 expression in primary and exploratory cohorts.

From: Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial

Fig. 2

a, Univariate analysis of baseline HER2 biomarker status and ORR in the primary cohort T-DXd arm. b, ORR based on biomarker status in the exploratory cohorts (HER2-low). c, OS by adjusted plasma HER2 copy number, HER2ECD in the primary cohort and HER2ECD in the exploratory cohorts. d, Forest plot of OS. a, HER2 mRNA gene expression median 9.72; serum HER2ECD median 9.72. b, Dashed vertical line represents overall ORR. a,b, Error bars represent 95% CI. d, HR < 1 favors the biomarker-selected group. Error bars represent 95% CI. aFor OS by HER2 ApCN, an exploratory cutoff (apCN 18.2) value was determined that minimized the P value estimated by log-rank test. Patients with values below 18.2 included those with no amplification. bFor OS according to HER2ECD, an exploratory cutoff value (14.4 ng ml−1 in the primary cohort, 11.6 ng ml−1 in the exploratory cohorts) was determined that minimized the P value estimated by log-rank test. Mut, mutant.

Back to article page